

**Supplementary Table 1. Summary of frequency of clinically significant exacerbations in Korean patients from the DREAM and MENSA studies<sup>a</sup>**

No. of exacerbations	DREAM				MENSA		
	Placebo (n = 6)	Mepolizumab 75 mg IV (n = 5)	Mepolizumab 250 mg IV (n = 7)	Mepolizumab 750 mg IV (n = 6)	Placebo (n = 15)	Mepolizumab 75 mg IV (n = 15)	Mepolizumab 100 mg SC (n = 15)
0	1 (17)	2 (40)	3 (43)	3 (50)	6 (40)	8 (53)	11 (73)
1	1 (17)	1 (20)	1 (14)	1 (17)	3 (20)	5 (33)	3 (20)
2	2 (33)	1 (20)	2 (29)	0	1 (7)	1 (7)	0
3	1 (17)	0	1 (14)	0	1 (7)	0	0
4	0	0	0	1 (17)	2 (13)	0	0
5	0	0	0	0	0	0	0
6	1 (17)	1 (20)	0	0	2 (13)	1 (7)	0
7	0	0	0	0	0	0	1 (7)
8	0	0	0	1 (17)	0	0	0
9	0	0	0	0	0	0	0
≥ 10	0	0	0	0	0	0	0

Values are presented as number (%).

DREAM, Dose Ranging Efficacy And safety with Mepolizumab in severe asthma; MENSA, Mepolizumab as adjunctive therapy in patients with Severe Asthma; IV, intravenous; SC, subcutaneous.

<sup>a</sup>Total treatment period was 52 weeks (DREAM) and 32 weeks (MENSA).